S6k , ERKs and p38 kinase. These results demonstrated that B[a]PDE was able to induce AP-1 transactivation and this AP-1 induction was specific through PI-3K/Akt/JNKs-dependent and p70 S6k -independent pathways. This study also indicated that Akt-T308A/ S473A blocks B[a]PDE-induced AP-1 activation specific through impairing JNK pathway. These findings will help us to understand the signal transduction pathways involved in the carcinogenic effects of B[a]PDE.
Introduction
Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environmental pollutants that have been found in cigarette smoke and charred foods, as well as the output from internal combustion engines and power plants (Conney, 1982; Phillips, 1983; Bostrom et al., 2002) . Exposures to PAHs are associated with an increased risk of lung and skin cancer (Merimsky and Inbar, 1998; Smith et al., 2000) . PAHs express their carcinogenic and other toxic effects after metabolic activation to reactive metabolites that bind to critical cellular constitutes (Heidelberger, 1973; Sims and Grover, 1974; Conney, 1982) . The metabolic activation of B[a]P has been extensively studied and is well understood (Selkirk et al., 1982; Cosman et al., 1992; Nebert et al., 1993; Conney et al., 1994) . The major sequence involves initial epoxidation of B[a]P by cytochrome P-450 1A1 to B[a]P-7,8-oxide. Hydrolysis of B[a]P-7,8-oxide to the B[a]P-7,8-dithdrodiol is catalysed by epoxide hydrolase. Recently, cytochrome P-450 1B1 has also been shown to be capable of metabolizing B[a]P to B[a]P-7,8-dithdrodiol in the presence of epoxide hydrolase (Shimada et al., 1999) . B[a]P-7,8-dithdrodiol is further metabolized to B[a]PDE by cytochrome P-450 3A4 or prostaglandin H synthase (Conney et al., 1994) . Benzo [a]pyrene-7,8-diol-9,10-epoxide (B[a] PDE) is an ultimate metabolite of B[a]P, and is able to interact with nucleophilic sites on cellular DNA, RNA and protein (Heidelberger, 1973; Sims and Grover, 1974; Conney, 1982; Selkirk et al., 1982; Cosman et al., 1992; Nebert et al., 1993; Conney et al., 1994; Shimada et al., 1999) . Carcinogenic activity of B[a]P and its metabolite, B[a]PDE, have been convincingly proven by previous studies from both in vitro and in vivo, and are actively involved in the development of smoking-associated cancers (Merimsky and Inbar, 1998; Smith et al., 2000) .
Carcinogenesis is a multistage process that encompasses multiple genetic and epigenetic events (DiGiovanni, 1992; Pitot, 1996) . These events can be divided into three independent stages: initiation, promotion and progression. Initiation is rapid and irreversible and occurs at a high frequency, whereas promotion is a longterm process that requires chronic exposure to a tumor promoter (Pitot, 1996; Huang et al., 1997a) . The rate-limiting steps in multistage carcinogenesis are now understood to occur during tumor promotion and tumor progression. Understanding the molecular basis of these steps is important for prevention of carcinogenesis. It is apparent that the cellular evolution to malignancy involves the sequential mutation of proto-oncogenes and/or tumor-suppressor genes, which are associated with initiation. Tumor promoter exposure results in activation of transcription factors and regulation of their target genes through signal transduction pathways, which have been characterized as tumor promotion and progression stages.
B [a] P is only one of many PAHs found in the complex mixture of chemicals in cigarette smoke (Smith et al., 2000) . It has been reported that B[a]P concentration is as high as 10-50 ng per cigarette (Hecht et al., 1974; Hoffmann et al., 1997) . B[a]P induces hepatic tumors in several animal models, including rats and mice (Hecht et al., 1974; Merimsky and Inbar, 1998; Smith et al., 2000) . B [a] PDE is mutagenic in species from bacteria to human (Eisenstadt et al., 1982; Bernelot-Moens et al., 1990; Rodriguez and Loechler, 1993) . B[a]P and its metabolite, B[a]PDE, have been shown to be a complete carcinogen in various animal models (Hecht et al., 1974; Levin et al., 1977; Buening et al., 1978; Merimsky and Inbar, 1998; Smith et al., 2000) . In the assay using the multistage carcinogenesis model in mouse skin, the induction of skin tumors in mice by B[a]PDE is accomplished by a multistage process involving both initiation and promotion Buening et al., 1978; Slaga et al., 1979) . The initiation effect of B[a]PDE is observed in mouse skin by the topical application of a single dose of B[a]PDE, followed with twice weekly applications of a tumor promoter, such as TPA, for 24 weeks (Slaga et al., 1979 (Bresnick et al., 1977; Levin et al., 1977; Albert et al., 1991) , their tumor promotion mechanisms, which are thought to be mediated through initiating signal transduction pathways leading to activation of transcription factors and their target genes, are barely understood.
Mouse epidermal JB6 Cl41 cells are a well-characterized and widely used cell culture model for tumor promotion studies (Bernstein and Colburn, 1989; Dong et al., 1994 Dong et al., , 1995 Huang et al., 1998; Watts et al., 1998) . Cl41 cells have proven to be valuable in studying tumor promotion, because they include variants in a promotable stage (Dong et al., 1995; Huang et al., 1998) . In transformation-sensitive (P þ ) but not transformationresistant (PÀ) JB6 cell lines, tumor promoters, such as phorbol esters or epidermal growth factors, induce AP-1 activity and neoplastic transformation (Bernstein and Colburn, 1989; Huang et al., 1998) . The AP-1 molecular inhibitor TAM67 (a transactivation domain deletion mutant of cJun) acts to sequester Jun and Fos family proteins in low activity complexes (Dong et al., 1994) . In JB6 cells, inhibition of AP-1 induction by TAM67 or by AP-1 transrepressing retinoids blocks 12-O-tetradecanoylphorbol 13-acetate (TPA)-and epidermal growth factor (EGF)-induced AP-1 transactivation and cell transformation (Dong et al., 1994; Huang et al., 1997a) . Several other events, such as activation of ERKs, NFkB and PI-3K, are also found to be required for TPA-or EGF-induced tumor promotion (Huang et al., 1996 Li et al., 1997; Watts et al., 1998) . Importantly, this cell line is derived from mouse skin and, thus, the results generated from Cl41 cells will provide a strong basis for further investigation in vivo in mouse skin. Therefore, in this study, we investigated possible AP-1 activation by B[a]PDE, and the signal transduction pathways leading to this activation. Figure 1b) . These results are consistent with previous findings that high doses of B[a]P are required for induction of AP-1 DNA-binding activities (Parrish et al., 1998 (Parrish et al., , 2002 . Our results demonstrated that B[a]PDE is a major metabolite responsible for AP-1 transactivation, suggesting that diol epoxide of B[a]PDE is necessary for induction of AP-1 activation.
Results

Induction
Induction of PI-3K activity in mouse epidermal C141 cells by B[a]PDE
It has been demonstrated that PI-3K activation plays an important role in tumor promotion by different carcinogens in different systems (Huang et al., 1996 (Huang et al., , 1997b Chang et al., 1997; Cantley and Neel, 1999; Aoki et al., 2000; Gonzales and Bowden, 2002) . It is also reported that B[a]P exposure may lead to increase in PI-3K activity in human mammary epithelial MCF-10A cells (Tannheimer et al., 1998) . Thus, it was important to determine whether PI-3K is involved in cell responses to B[a]PDE. As shown in Figure 2 It has previously been established that PI-3K activation is required for TPA-or EGF-induced AP-1 activation (Huang et al., 1996 (Huang et al., , 1997b . Since the above results suggested that both AP-1 and PI-3K are activated in Cl41 cells in response to B[a]PDE exposure, it was of interest to determine the role of PI-3K in B[a]PDEstimulated AP-1 transactivation in C141 cells. Thus, we first determined the effect of wortmannin and Ly294002, PI-3K inhibitors that inhibit PI-3K activation by targeting p110 and p85 subunits of PI-3K, respectively, on B[a]PDE-induced AP-1 activation. The results showed that the induction of AP-1 activity by cells was significantly inhibited by pretreatment of cells with either one of the inhibitors (Figure 3a) . These inhibitions appeared to be in a time-and dose-dependent manner (Figure 3b and c) . The results suggested that PI-3K may be involved in B[a]PDE-induced AP-1 activation in Cl41 cells. To further explore this, we utilized a stable transfectant, Cl41 AP-1 Dp85 mass1, which is well characterized in our previous studies as a transfectant with a dominant-negative mutant of PI-3K, Dp85 (Huang et al., 1996 (Huang et al., , 1997b ). An overexpression of Dp85 dramatically inhibited B[a]PDE-induced PI-3K activation ( Figure 4 ). As shown in Figure 5 , inhibition ) cells were seeded into each of 100-mm dishes. The media were replaced with 0.1% FBS MEM after the cell density reached 70-80% confluency. After 45 h, the cells were incubated with fresh serum-free MEM medium for 3-4 h at 371C. Cells were exposed to 2 mM B[a]PDE for 20 min. Cells were washed once with ice-cold PBS and lysed in 400 ml of lysis buffer. PI-3K activity was measured as described in Materials and methods 
Overexpression of dominant-negative mutant Akt impaired B[a]PDE-induced AP-1 activation in Cl41 cells
Since our results indicated that PI-3K is involved in signal transduction in response to B[a]PDE, leading to AP-1 activation, it was important to elucidate further PI-3K downstream signaling kinases. It is known that Akt is one of the key PI-3K downstream kinases in Cl41 cells in response to UV radiation demonstrated in our previous studies (Huang et al., 2001) . To determine whether Akt is involved in B[a]PDE-induced AP-1 transactivation, we established a stable transfectant, Cl41 AP-1 Akt-T308A/S473A mass1. The results showed that B[a]PDE exposure resulted in an increase in phosphorylation of Akt at Thr308 and at Ser473 (Figures 6 and 7), which were shown to be the key steps for activation of Akt (Burgering and Coffer, 1995), S6k is another important PI-3K downstream kinase in Cl41 cells (Huang et al., 2002a, b) . To test its role in B[a]PDE-induced AP-1 activation, we investigated the possible activation of p70 S6k in B[a]PDE-treated cells. Figure 7 showed that exposure of cells to B[a]PDE resulted in an increase in phosphorylation of p70
S6k at Thr389 and Thr421/Ser424 (Figure 7 ). An introduction of Dp85 only inhibited B[a]PDE-induced phosphorylation of p70
S6k at Thr389 and Thr421/Ser424 in an early phase (60 min after BPDE exposure), but not in a later phase (Figure 7) , while an overexpression of SRa-Akt-T308A/S473A did not show any inhibitory effect (Figure 8a ), indicating that p70 S6k activation is partially through a PI-3K-dependent, and not through Aktdependent pathway. Furthermore, inhibition of p70 S6k phosphorylation at Thr389 and Thr421/Ser424 at the same doses ( Figure 6) S6k phosphorylation at Thr389 and Thr421/Ser424 through both PI-3K-dependent and -independent pathways, and Akt activation is not critical for p70
S6k activation.
Inhibition of PI-3K/Akt pathway impaired B[a]PDE-induced AP-1 activation specific through inhibition of JNK activation
AP-1 has been identified as a target of the MAPK family, including ERKs, JNKs and p38 kinase (Karin et al., 1997) . To study the mechanism that mediates the inhibition of AP-1 activation by an introduction of dominant-negative mutant Akt, SRa-Akt-T308A/ S473A, the effects of B or Cl41 AP-1 Dp85 mass1 were seeded into each of 100-mm dishes. The media were replaced with 0.1% FBS MEM after the cell density reached 70-80% confluency. After 45 h, the cells were incubated with fresh serum-free MEM medium for 3-4 h at 371C. Cells were exposed to 2 mM B[a]PDE for various time points as indicated. Cells were washed once with ice-cold PBS and lysed in 400 ml of lysis buffer. PI-3K activity was measured as described in Materials and methods. The results are from one of three independent experiments (Hall et al., 1989) . Tumorigenicity of B[a]PDE was tested on female CD-1 and Sencar mice (Hecht et al., 1974; Buening et al., 1978; Merimsky and Inbar, 1998; Smith et al., 2000) . B[a]PDE is able to induce lung adenomas in newborn mice (Buening et al., 1978 Slaga et al., 1979; Albert et al., 1991) . Significant tumor initiation of B[a]PDE was found by topical application of B[a]PDE followed with twice weekly applications of TPA for 24 weeks (Slaga et al., 1979) . In contrast, repeated topical applications of B[a]PDE on mouse skin were very effective in causing hyperplasia, which revealed the tumor promotion activity (Bresnick et al., 1977 , Albert et al., 1991 (Eisenstadt et al., 1982; Bernelot-Moens et al., 1990; Yang et al., 1991; Rodriguez and Loechler, 1993) . However, the critical molecular events involved in B[a]PDE tumor promotion remain to be elucidated, even though some recent evidence suggests that B[a]P is able to cause activation of proto-oncogenes, such as cHa-ras (Bral and Ramos, 1997) . AP-1 is an important transcription factor governing the expression of genes involved in intercellular communication, amplification or spreading of primary pathogenic signals, as well as initiation or acceleration of tumorigenesis (Smith and Prochownik, 1992; Karin et al., 1997) . The requirement of AP-1 for tumor promotion has been demonstrated in various cell models by a number of groups (Bernstein and Colburn, 1989; Kovary and Bravo, 1991; Dong et al., 1994 Dong et al., , 1995 Huang et al., 1996 Huang et al., , 1997a Huang et al., , b, 1998 Huang et al., , 1999 Li et al., 1997; Watts et al., 1998; Young et al., 1999; Thompson et al., 2002; Cooper et al., 2003) . Activation of AP-1 appears to be required for the preneoplastic-to-neoplastic progression of JB6 cells (Bernstein and Colburn, 1989; Dong et al., 1994 Dong et al., , 1995 Huang et al., 1996 Huang et al., , 1997b Li et al., 1997; Watts et al., 1998) . Overexpression of c-Jun in Cl41 cells caused neoplastic transformation and the introduction of a dominant-negative mutant of c-Jun blocked tumor promoter-induced cell transformation (Dong et al., 1994) . Also, blocking AP-1 activity by either pharmacological inhibitors or molecular biological inhibitors also impairs tumor development. These inhibitors include PD98059, SB202190, wortmannin, Ly294002, Insp6, fluocinolane acetonide, retinoic acid, ascorbic acid, dominant-negative ERK2, dominantnegative JNK1 and dominant-negative P1-3K (Huang et al., 1996 (Huang et al., , 1997a (Huang et al., , b, 1999 Li et al., 1997; Watts et al., 1998; Young et al., 1999) . The acquisition of a tumor promotion-resistant phenotype is associated with the loss of responsiveness to tumor promoter-induced AP-1 activation (Bernstein and Colburn, 1989; Huang et al., 1998) . Introducing wild-type ERK2, a direct upstream kinase involved in AP-1 activation, converts a tumor promotion-resistant phenotype to a tumor promotionsensitive phenotype . In contrast, overexpression of dominant-negative mutant ERK2 blocks TPA-or EGF-induced AP-1 activation and cell transformation (Watts et al., 1998) . The important role of AP-1 in tumor promotion was further supported by findings using dominant-negative mutant c-jun transgenic mice, in which transactivation mutant c-jun (TAM67), under the control of the human keratin-14 promoter, is expressed specifically in the basal cells of the epidermis where tumor induction is initiated. . Subconfluent (90%) monolayers of Cl41 cells in six-well plates were subjected to either wortmannin (100 nM), Ly294002 (10 mM) or rapamycin (20 mM) for 30 min. The cells were then exposed to B[a]PDE (2 mM) for various time points as indicated. The cells were washed once with ice-cold PBS and extracted with SDS-sample buffer. The cell extracts were separated on polyacrylamide-SDS gels, transferred and probed with one of the specific antibodies as indicated. The protein band specific bound with primary antibodies was detected by using anti-rabbit IgG-AP-linked and ECF Western blotting system. The results are from one of three independent experiments CL41 AP-1 mass1 CL41 AP-1 ∆p85 mass1 Figure 7 Effects of overexpression of Dp85 on phosphorylation of Akt and p70 S6k induced by B[a]PDE. Subconfluent (90%) monolayers of Cl41 AP-1 mass1, Cl41 AP-1 Dp85 mass1 in six-well plates were subjected to B[a]PDE (2 mM) for various time points as indicated. The cells were then washed once with ice-cold PBS and extracted with SDS-sample buffer. The cell extracts were separated on polyacrylamide-SDS gels, transferred and probed with one of the specific antibodies as indicated. The protein band specific bound with primary antibodies was detected by using anti-rabbit IgG-AP-linked and ECF Western blotting system. The results are from one of three independent experiments Signaling pathways leading to AP-1 activation by B[a]PDE J Li et al TAM67 mice (Young et al., 1999) . In two-stage skin carcinogenesis experiments, these mutant c-jun transgenic mice showed a dramatic inhibition in papilloma induction by TPA, okadaic acid and UV radiation (Thompson et al., 2002; Cooper et al., 2003) . Thus, there is strong in vitro and in vivo evidence that transactivation of AP-1 is required for tumor promotion and, thus, AP-1 may be targeted for cancer prevention. PI-3K is a dimeric enzyme composed of a catalytic subunit (p110) and a regulatory subunit (p85) (Carpenter et al., 1990) , and phosphorylates the lipid phosphatidylinositol (PI) (Whitman et al., 1988) . PI-3K and its products, PI(3,4)P 2 and PI(3,4,5)P 3 , are important regulators of cell mitogenic signaling, cell survival, cytoskeletal remodeling, metabolic control and vesicular trafficking (Jhun et al., 1994; Hu et al., 1995; Myers and White, 1996; Alessi and Downes, 1998; Shepherd et al., 1998) . PI(3,4)P 2 and PI(3,4,5)P 3 are elevated in cells transformed by the oncogene v-abl, v-src and polyoma middle T, and decreased levels of these lipids correlate with impaired cell transformation by mutated forms of these oncogenes (Cantley et , subconfluent (90%) monolayers of Cl41 AP-1 mass4 or Cl41 AP-1 DN-Akt T308A/S473A in six-well plates were subjected to B[a]PDE (2 mM) for 120 min. The cells were extracted and Western blot was carried out as described in Materials and methods. The results are from one of three independent experiments. (b, c) Cl41 AP-1 mass4 (8 Â 10 Varticovski et al., 1991) . Our previous studies have demonstrated that PI-3K activation is required for TPA-or EGF-induced AP-1 transactivation and cell transformation (Huang et al., 1996 (Huang et al., , 1997b ). This conclusion is based on the observation that inhibition of PI-3K with either PI-3K chemical inhibitors (wortmannin and LY294002) or a dominant-negative PI-3K impaired TPA-and EGF-induced AP-1 activation and cell transformation (Huang et al., 1996 (Huang et al., , 1997b . In this study, we show that B[a]PDE is able to induce activation of both PI-3K and AP-1, revealing that there might be some association between the AP-1 and PI- Akt has been found to be a downstream kinase that is involved in PI-3K pathway. Activation of Akt is dependent upon its phosphorylation (Varticovski et al., 1991; Kapeller and Cantley, 1994; Datta et al., 1999) . Physiologic stimuli, such as EGF, are capable of inducing Akt kinase activity involving PI-3K (Datta et al., 1999) . The results from our most recent studies demonstrated that UV radiation leads to increased Akt phosphorylation at Thr 308 and Ser 473 through PI-3K-dependent pathway in Cl41 cells. In contrast, increased calcium binds to calmodulin and the Ca 2 þ /calmodulin complex also activates the calcium/calmodulin-dependent kinase kinase (CaMKK), which then activates Akt by directly phosphorylating Akt at the Thr 308 (Yano et al., 1998) . Thus, Akt could be activated through either PI-3K-dependent or -independent pathways (Myers and White, 1996; Shepherd et al., 1998) . This reveals that it is necessary to determine whether Akt is a PI-3K downstream kinase responsible for AP-1 activation by B[a]PDE. It was found in this study that specific blockade Akt activation by the introduction of dominant-negative mutant Akt specific impairs B[a]PDE-induced activation of AP-1 and JNKs, but not ERKs and p38 kinase. These data indicate that Akt is a PI-3K downstream kinase and mediates B[a]PDE-induced AP-1 activation specific through the JNK pathway. The requirement of the PI-3K/Akt/JNK pathway for AP-1 activation was also supported by a very recent finding that tumor necrosis factor receptor-associated factor 6 (TRAF6) and c-Srcinduced JNK activation were significantly inhibited by PI3-kinase inhibitor or a dominant-negative mutant of Akt (Funakoshi-Tago et al., 2003) . Although mechanisms by which dominant-negative Akt inhibits JNKs activation have not been fully defined yet, there are several evidences showing that Akt may interact with JNKs indirectly in cells (Kim et al., 2002; FunakoshiTago et al., 2003; Lee et al., 2003) .
The p70 S6 kinase ( p70 S6k ) is another kinase that may act as a PI-3K downstream kinase (Jeno et al., 1988; Proud, 1996) . The evidence from previous studies has pointed to an important role of p70 S6k in the regulation of cell growth, transformation and transition of cell cycle in mammalian cells (Susa et al., 1989; Reinhard et al., 1992 (Ferrari et al., 1992; Han et al., 1995; Pearson et al., 1995) . The PI-3K structurally related enzyme mTOR (also termed FRAP or RAFT) is involved in the regulation of p70 S6k phosphorylation (Toker, 2000) , which is a key step for activation of p70
S6k
. Our most recent data also indicated that p70
S6k activation by UV radiation is independent of Akt. We found here that B -independent pathway. This conclusion is based on the results provided from using chemical inhibitors, including wortmannin, Ly294002 and rapamycin, or overexpression of dominant-negative mutants, such as Dp85 and SRa-Akt-T308A/S473A. Based on the data shown in this study, we summary the signaling pathways leading to AP-1 induction and tumor promotion by B[a]PDE exposure, as shown in Figure 11 .
Materials and methods
Plasmids and reagents
CMV-neo vector plasmid, Akt mutant plasmid (SRa-Akt-T308A/S473A) and dominant-negative mutant PI-3K plasmid (Dp85) were as described in previous reports (Bernstein and Colburn, 1989; Huang et al., 1996 Huang et al., , 1997b Huang et al., , 1998 Li et al., 1997; Watts et al., 1998) S6k pathway inhibitor, were purchased from Calbiochem (La Jolla, CA, USA). LipofectAMINE was obtained from GIBCO BRL.
Cell culture
The JB6 P þ mouse epidermal Cl41 cell line and its transfectants were cultured in monolayers at 371C, 5% CO 2 , using MEM containing 5% fetal calf serum (FBS), 2 mM Lglutamine, and 25 mg gentamicin per ml, as described previously (Huang et al., 1996 (Huang et al., , 1997b . The cultures were dissociated with trypsin and transferred to new 75 cm 2 culture flasks (Fisher, Pittsburgh, PA, USA) from one to three times per week.
Generation of stable cotransfectants
Cl41 cells were cultured in a six-well plate until they reached 85-90% confluence. In all, 1 mg of CMV-neo vector and 20 ml of LipofectAMINE reagent, with 2 mg of AP-1-luciferase reporter plasmid DNA, mixed together with 12 mg of dominant-negative mutant (SRa-Akt-T308A/S473A) or vector control, were used to transfect each well in the absence of serum. After 10-12 h, the medium was replaced with 5% FBS MEM. Approximately 30-36 h after the beginning of the transfection, the cells were digested with 0.033% trypsin and cell suspensions were plated onto 75 ml culture flasks and cultured for 24-28 days with G418 selection (400 mg/ml). The stable transfectants were identified by measuring both the basal level of luciferase activity and the blocking Akt activation. Stable transfectants, Cl41 AP-1 mass4 and Cl41 AP-1 Akt-T308A/S473A mass1 were established and cultured in G418-free MEM for at least two passages before each experiment.
AP-1 activity assay
Confluent monolayers of P þ 1-1 cells or Cl41 cell stable transfectants were trypsinized, and 8 Â 10 3 viable cells suspended in 100 ml of MEM supplemented with 5% FBS were added to each well of a 96-well plate. The plates were incubated at 371C in a humidified atmosphere with 5% CO 2 in air. After the cell density reached 80-90%, cells were exposed to B[a]PDE at a final concentration, as indicated in the figure legends for AP-1 induction. At different periods of time after treatment, the cells were extracted with lysis buffer (Promega, Madison, WI, USA), and their luciferase activity was determined by the Luciferase assay using a luminometer (Wallac 1420 Victor 2 multilabel counter system) after the addition of 100 ml of lysis buffer for 30 min at 41C. The results are expressed as AP-1 activity relative to control medium containing the same concentration of DMSO only (relative AP-1 activity).
MAPK phosphorylation assay
Cl41 cells were cultured in monolayers in six-well plates. After the cell density reached 70-80%, the serum in the medium was reduced from 5 to 0.1%. Cells were incubated in MEM containing 0.1% serum and 2 mM L-glutamine for 3-4 h at 371C. Cells were then incubated with B[a]PDE for different periods of time and extracted with Tris-Glycine SDS sample buffer (Invitrogen, Carlsbad, CA, USA). Western blots were performed with either phospho-specific antibodies or nonphosphorylated antibodies against various kinases, including ERKs, JNKs and p38 kinase. The protein band specifically bound to the primary antibody was detected using an antirabbit IgG-AP-linked and an ECF Western blotting system (Amersham Biosciences, Piscataway, NJ, USA).
PI-3 kinase assay
PI-3 kinase activities were assayed as described in our previous reports (Huang et al., 1996 (Huang et al., , 1997b . In brief, cells were cultured in monolayers in 100-mm dishes using normal culture medium. The media were replaced with 0.1% FBS MEM containing 2 mM L-glutamine and 25 mg of gentamicin/ml after the cell density reached 70-80%. After 45 h, the cells were incubated with fresh serum-free MEM medium for 3-4 h at 371C. B[a]PDE was then added to cell cultures for PI-3K induction. Cells were washed once with ice-cold PBS and lysed in 400 ml of lysis buffer per plate (20 mM Tris, pH 8, 137 mM NaCl, 1 mM MgCl 2 , 10% glycerol, 1% Nonidet P-40, 1 nM dithiothreitol, 0.4 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride). The lysates were centrifuged and the supernatants incubated at 41C with 40 ml of agarose beads (previously conjugated with the monoclonal antiphosphotyrosine antibody Py20) overnight). Beads were washed twice with each of the following buffers: (1) phosphate-buffered saline with 1% Nonidet P-40, 1 mM dithiothreitol; (2) 0.1 M Tris (pH 7.6), 0.5 M LiCl, l mM dithiothreitol; and (3) 10 mM Tris (pH 7.6), 0.1 M NaCl, 1 mM dithiothreitol. Beads were incubated for 5 min on ice in 20 ml of buffer 3, and then 20 ml of 0.5 mg/ml phosphatidylinositol (previously sonicated in 50 mM HEPES (pH 7.6), 1 mM EGTA, 1 mM NaH 2 PO 4 ) was added. After 5 min at room temperature, 10 ml of the reaction buffer was added (50 mM MgCl 2 , 100 mM HEPES (pH 7.6), 250 mM ATP containing 5 mCi of [g-32 P] ATP), and beads were incubated for an additional 15 min. Reactions were stopped by the addition of 15 ml of 4 N HCl and 130 ml of chloroform : methanol (1 : 1). After vortexing for 30 s, 30 ml from the phospholipid-containing chloroform phase was spotted onto thin-layer chromatography plates coated with silica gel H containing 1.3% potassium oxalate and 2 mM EDTA applied in H 2 O : methanol (3 : 2). Plates were heated at 1101C for at least 3 h before use. Plates were then placed in tanks containing chloroform : methanol : NH 4 OH : H 2 O (600 : 470 : 20 : 113) for 40-50 min, until the solvent reaches the top of the plates. Plates were dried at room temperature and autoradiographed (Huang et al., 1996 (Huang et al., , 1997b .
Phosphorylation assay for Akt and p70
S6k
Cl41 transfectants (3 Â 10 4 ) were cultured in each well of a sixwell plate to 70-80% confluence with normal culture medium. The cell culture medium was replaced with 0.1% FBS MEM with 2 mM L-glutamine and 25 mg of gentamicin and cultured for 33 h. Cells were incubated in serum-free MEM for 3-4 h at 371C. Cells were exposed to B[a]PDE for various time points. Cells were washed once with ice-cold PBS and extracted with an SDS-sample buffer. The cell extracts were separated on polyacrylamide-SDS gels, transferred and probed with one of the antibodies, including rabbit phospho-specific Akt (Thr308) antibody, phospho-specific Akt (Ser473) antibody, no-phosphorylated Akt antibody, phospho-specific p70 S6k bound to primary antibodies will be detected using an antirabbit IgG-AP-linked and by an ECF Western blotting system (Huang et al., 2001 .
Statistical analysis
The Student's t-test was used to determine the significance of differences of AP-1 activities between B[a]PDE treated and DMSO alone. The differences were considered significant at a Po0.05. 
